Charles Schwab
SCPS

Charles Schwab’s Scopus BioPharma Inc. Common Stock SCPS Stock Holding History

Charles Schwab’s Portfolio SCPS Stock Details SCPS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-11,810
Closed -$100K – 3585
2021
Q1 		$100K Buy
+11,810
New +$124K ﹤0.01% 3381

Other funds holding SCPS

BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab's SCPS Position: Q2 2021 in Review

Charles Schwab sold out of Scopus BioPharma Inc. Common Stock (SCPS) in Q2 2021, closing a stake of 11,810 shares — an estimated $100K sold.

Charles Schwab first reported a position in SCPS in Q1 2021 and held it in 1 quarter. The position peaked at $100K in Q1 2021. 15 funds tracked by Wall St. Rank hold SCPS as of Q2 2021.

  • Charles Schwab reported no remaining Scopus BioPharma Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Charles Schwab sold 11,810 Scopus BioPharma Inc. Common Stock shares in Q2 2021, an estimated $100K.
  • Charles Schwab first reported a position in Scopus BioPharma Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Charles Schwab's Scopus BioPharma Inc. Common Stock position peaked at $100K in Q1 2021.
  • 15 funds tracked by Wall St. Rank held Scopus BioPharma Inc. Common Stock as of Q2 2021.

Based on Charles Schwab's 13F filing for Q2 2021, filed 16 Aug 2021.